Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 80

1.

Incidence of invasive breast cancer in postmenopausal women after discontinuation of long-term raloxifene administration.

Vogel VG, Qu Y, Wong M, Mitchell B, Mershon JL.

Clin Breast Cancer. 2009 Feb;9(1):45-50. doi: 10.3816/CBC.2009.n.008.

PMID:
19299240
[PubMed - indexed for MEDLINE]
2.

Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.

Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, Secrest RJ, Cummings SR; CORE Investigators.

J Natl Cancer Inst. 2004 Dec 1;96(23):1751-61.

PMID:
15572757
[PubMed - indexed for MEDLINE]
Free Article
3.

Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.

Siris ES, Harris ST, Eastell R, Zanchetta JR, Goemaere S, Diez-Perez A, Stock JL, Song J, Qu Y, Kulkarni PM, Siddhanti SR, Wong M, Cummings SR; Continuing Outcomes Relevant to Evista (CORE) Investigators.

J Bone Miner Res. 2005 Sep;20(9):1514-24. Epub 2005 May 16.

PMID:
16059623
[PubMed - indexed for MEDLINE]
4.

Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.

Burshell AL, Song J, Dowsett SA, Mershon JL, Delmas PD, Secrest RJ, Cauley JA.

Curr Med Res Opin. 2008 Mar;24(3):807-13. doi: 10.1185/030079908X273282. Epub 2008 Feb 5.

PMID:
18254988
[PubMed - indexed for MEDLINE]
5.

Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk.

Lippman ME, Cummings SR, Disch DP, Mershon JL, Dowsett SA, Cauley JA, Martino S.

Clin Cancer Res. 2006 Sep 1;12(17):5242-7.

PMID:
16951244
[PubMed - indexed for MEDLINE]
Free Article
6.

Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation.

Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, Farrerons J, Karasik A, Mellstrom D, Ng KW, Stepan JJ, Powles TJ, Morrow M, Costa A, Silfen SL, Walls EL, Schmitt H, Muchmore DB, Jordan VC, Ste-Marie LG.

Breast Cancer Res Treat. 2001 Jan;65(2):125-34. Erratum in: Breast Cancer Res Treat 2001 May;67(2):191.

PMID:
11261828
[PubMed - indexed for MEDLINE]
7.

Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk.

Grady D, Cauley JA, Geiger MJ, Kornitzer M, Mosca L, Collins P, Wenger NK, Song J, Mershon J, Barrett-Connor E; Raloxifene Use for The Heart Trial Investigators.

J Natl Cancer Inst. 2008 Jun 18;100(12):854-61. doi: 10.1093/jnci/djn153. Epub 2008 Jun 10.

PMID:
18544744
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Safety assessment of raloxifene over eight years in a clinical trial setting.

Martino S, Disch D, Dowsett SA, Keech CA, Mershon JL.

Curr Med Res Opin. 2005 Sep;21(9):1441-52.

PMID:
16197663
[PubMed - indexed for MEDLINE]
9.

Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis.

Ensrud K, Genazzani AR, Geiger MJ, McNabb M, Dowsett SA, Cox DA, Barrett-Connor E.

Am J Cardiol. 2006 Feb 15;97(4):520-7. Epub 2006 Jan 4.

PMID:
16461049
[PubMed - indexed for MEDLINE]
10.

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER Jr, Wade JL 3rd, Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N; National Surgical Adjuvant Breast and Bowel Project (NSABP).

JAMA. 2006 Jun 21;295(23):2727-41. Epub 2006 Jun 5. Erratum in: JAMA. 2006 Dec 27;296(24):2926. JAMA. 2007 Sep 5;298(9):973.

PMID:
16754727
[PubMed - indexed for MEDLINE]
11.

Long-term raloxifene for postmenopausal osteoporosis.

Recker RR, Mitlak BH, Ni X, Krege JH.

Curr Med Res Opin. 2011 Sep;27(9):1755-61. doi: 10.1185/03007995.2011.606312. Epub 2011 Jul 25. Review.

PMID:
21787127
[PubMed - indexed for MEDLINE]
12.

The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.

Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC.

JAMA. 1999 Jun 16;281(23):2189-97. Erratum in: JAMA 1999 Dec 8;282(22):2124.

PMID:
10376571
[PubMed - indexed for MEDLINE]
13.

Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants.

Lippman ME, Krueger KA, Eckert S, Sashegyi A, Walls EL, Jamal S, Cauley JA, Cummings SR.

J Clin Oncol. 2001 Jun 15;19(12):3111-6. Erratum in: J Clin Oncol 2002 Mar 1;20(5):1430.

PMID:
11408508
[PubMed - indexed for MEDLINE]
Free Article
14.

Benefits and risks of raloxifene by vertebral fracture status.

Sontag A, Wan X, Krege JH.

Curr Med Res Opin. 2010 Jan;26(1):71-6. doi: 10.1185/03007990903427082.

PMID:
19908937
[PubMed - indexed for MEDLINE]
15.

Risk-benefit profile for raloxifene: 4-year data From the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial.

Barrett-Connor E, Cauley JA, Kulkarni PM, Sashegyi A, Cox DA, Geiger MJ.

J Bone Miner Res. 2004 Aug;19(8):1270-5. Epub 2004 Apr 12.

PMID:
15231013
[PubMed - indexed for MEDLINE]
16.

Raloxifene and tibolone in elderly women: a randomized, double-blind, double-dummy, placebo-controlled trial.

Jacobsen DE, Melis RJ, Verhaar HJ, Olde Rikkert MG.

J Am Med Dir Assoc. 2012 Feb;13(2):189.e1-7. doi: 10.1016/j.jamda.2011.05.005. Epub 2011 Jul 13.

PMID:
21741883
[PubMed - indexed for MEDLINE]
17.

Exemestane for breast-cancer prevention in postmenopausal women.

Goss PE, Ingle JN, Alés-Martínez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, McTiernan A, Robbins J, Johnson KC, Martin LW, Winquist E, Sarto GE, Garber JE, Fabian CJ, Pujol P, Maunsell E, Farmer P, Gelmon KA, Tu D, Richardson H; NCIC CTG MAP.3 Study Investigators.

N Engl J Med. 2011 Jun 23;364(25):2381-91. doi: 10.1056/NEJMoa1103507. Epub 2011 Jun 4. Erratum in: N Engl J Med. 2011 Oct 6;365(14):1361.

PMID:
21639806
[PubMed - indexed for MEDLINE]
Free Article
18.

Serum estradiol level and risk of breast cancer during treatment with raloxifene.

Cummings SR, Duong T, Kenyon E, Cauley JA, Whitehead M, Krueger KA; Multiple Outcomes of Raloxifene Evaluation (MORE) Trial.

JAMA. 2002 Jan 9;287(2):216-20.

PMID:
11779264
[PubMed - indexed for MEDLINE]
19.

Effect of long-term treatment with raloxifene on mammary density in postmenopausal women.

Lasco A, Gaudio A, Morini E, Morabito N, Nicita-Mauro C, Catalano A, Denuzzo G, Sansotta C, Xourafa A, Macrì I, Frisina N.

Menopause. 2006 Sep-Oct;13(5):787-92.

PMID:
16912660
[PubMed - indexed for MEDLINE]
20.

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Glüer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR.

JAMA. 1999 Aug 18;282(7):637-45. Erratum in: JAMA 1999 Dec 8;282(22):2124.

PMID:
10517716
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk